CSL stock prepares for CEO handover as Waterhouse starts in 2027

Published on 10/30/2026 at 15:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CSL stock is in focus ahead of a planned leadership handover to Deborah Waterhouse. The incoming CEO will take charge on February 1, 2027.

Leadership transition and FY27 outlook

Deborah Waterhouse will become CSL's chief executive and managing director on February 1, 2027.
Interim CEO Gordon Naylor will oversee the transition before returning to CSL's board as a non-executive director.
Management has retained its fiscal 2027 outlook for underlying net profit after tax growth of about 5 percent.

CSL, AU000000CSL8, Illustration mit AI erstellt.

CSL is preparing for a leadership transition after appointing Deborah Waterhouse as its next chief executive and managing director. CSL stock traded at EUR 125.69 on Lang & Schwarz at 3:08 p.m. CEST on Friday, October 30, 2026.

The quote was 1.97 percent above the EUR 123.26 level cited in the latest relevant report published on October 27. The comparison reflects the movement since that report and is separate from a daily Xetra comparison.

Waterhouse takes charge in February

CSL announced the appointment on October 21, saying Waterhouse will start on February 1, 2027, after an extensive global search. The CSL newsroom said she has led ViiV Healthcare since 2017 and previously held senior roles at GSK.

Interim CEO Gordon Naylor will remain in the role until the handover. He will then return to the board as a non-executive director, giving investors a defined transition plan while Waterhouse prepares to lead CSL's next phase.

Growth target remains central

The change comes as CSL works to restore reliable growth across its plasma, vaccines and specialty medicines businesses. At its annual general meeting, the company retained its fiscal 2027 outlook for revenue broadly in line with the previous year and underlying net profit after tax growth of about 5 percent.

Waterhouse has said her priorities will include sustaining commercial momentum, renewing CSL's pipeline and simplifying operations. For investors, execution against that outlook and the leadership handover will be the next key milestones.

Follow the real-time quote of CSL stock for the latest Lang & Schwarz indication.